Identify underlying allergy aetiology

Article

Search for common clues to complicating factors, including blephartis and dry eye

Aplethora of effective antihistamines does little to relieve ocular allergies when complicated by other concomitant factors, said Dr Michael B. Raizman, at the 29th annual Current Concepts in Ophthalmology conference held in association with the Wilmer Eye Institute.

"You would think allergy would be easy to treat," said Dr Raizman, associate professor of ophthalmology, Tufts University School of Medicine, Boston, Massachusetts, USA. "We have the best antihistamines in the world. They are incredibly effective, yet our patients still come in complaining. They've tried everything, and nothing is working. Why is that?"

Obvious allergic conjunctivitis

This condition is seasonal and caused by pollens in the air. Patients may complain that the overthecounter (OTC) eye drops they use no longer work, Dr Raizman said. The most common reason for this type of failure for allergy treatment is the presence of other conditions of the ocular surface.

"[More than] 75% of treatment failures are caused by either dry eye or blepharitis," he said.

"You must treat the allergy and the under­lying dry eye or blepharitis as well," Dr Raizman said. "Sometimes, many patients can have all three of these - to varying degrees."

The presence of dry eye may not always be obvious. In such cases, lissamine green staining and rose bengal staining are often useful.

"Try to think of all three together, and treat all of them," he said. "Patients may be describing what sound to you like allergies. You can treat their allergies all you want, but if their blepharitis is bothering them, they will view the allergy treatment as a failure."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.